Grail is collaborating with the U.S. Department of Veterans Affairs (VA) Health Administration on a large-scale observational study assessing the performance of its Galleri multicancer early-detection blood test.
Over the next three years, 10,000 veterans across the U.S. will receive Galleri and be able to enroll in the company's Reflection registry. The VA Pittsburgh Healthcare System will be the first of approximately 10 VA sites that will participate in the study, according to Grail.
